Vipergen Expands Glue Screening with Five E3 Ubiquitin Ligases

Vipergen has expanded its cell-based molecular glue screening platform with five E3 ubiquitin ligases: FBXO22, FEM1B, KBTBD4, SKP2 and SPOP – bringing the total number of ready-to-use ligases for screening to 25. 

With more than 600 identified in humans, E3 ubiquitin ligases play a central role in protein turnover and are essential to targeted protein degradation. By expanding its ligase panel, Vipergen enables partners to explore broader biological space and improve the chances of identifying molecular glue or PROTAC degraders for their targets. In addition, Vipergen offers tailored solutions, enabling rapid incorporation of new E3 ligases into its screening platform.

The newly incorporated ligases were selected based on features relevant to the drug discovery community, including robust expression in disease-relevant tissues, ligandability, compatibility with degrader modalities, interaction with disease-relevant targets and overall diversity to expand target space.

“With the addition of these five ligases, we continue to push the boundaries of what is possible in molecular glue discovery,” said Dr. Allan B. Christensen, Director of Screening Technologies at Vipergen. “Expanding our ligase panel enhances our ability to identify unique protein-protein interaction inducers and deliver high-quality starting points for drug discovery programs.”

This expansion further strengthens Vipergen’s position at the forefront of molecular glue discovery and reflects its mission to accelerate the discovery of next-generation therapeutics through novel modalities. 

About Vipergen ApS

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit https://www.vipergen.com.

For additional information please contact:

Vipergen ApS
info@vipergen.com